There’s no home court advantage for Mylan when it comes to the EpiPen controversy.
West Virginia’s attorney general Wednesday called on the Justice Department to reject an announced $465 million settlement from Mylan to resolve allegations that the big pharma company shortchanged the Medicaid system in rebates for sales of the anti-allergy device EpiPen.
AG Patrick Morrisey called that yet-to-be-signed settlement announced last month a “sweetheart deal” that is “irresponsible,” “woefully deficient,” and “not in the best interests of West Virginia” if the amount Mylan has said it will pay is correct.
